Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
Jieying Yang,
Li Fu,
Toshiro Shirakawa,
Toshiro Shirakawa,
Tong Xiang
Affiliations
Jieying Yang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
Li Fu
Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and Shenzhen International Cancer Centre, Shenzhen University School of Medicine, Shenzhen, China
Toshiro Shirakawa
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
Toshiro Shirakawa
Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan
Tong Xiang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
